Ptc Therapeutics, INC. (PTCT) — SEC Filings

Overview

Ptc Therapeutics, INC. (PTCT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 25, 2026: PTC Therapeutics, Inc. filed an 8-K on March 25, 2026, reporting on events from March 24, 2026. The filing specifically addresses Item 5.02, which covers changes in directors or officers and their compensation arrangements, and Item 7.01, related to Regulation FD Disclosure. This matters to investor

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 35 neutral. The dominant filing sentiment for Ptc Therapeutics, INC. is neutral.

Filing Type Overview

Ptc Therapeutics, INC. (PTCT) has filed 17 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 1 SC 13D/A, 1 SC 13G with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (38)

• PTC Therapeutics 8-K: Officer Changes, Comp Arrangements — 8-K · Mar 25, 2026
  PTC Therapeutics, Inc. filed an 8-K on March 25, 2026, reporting on events from March 24, 2026. The filing specifically addresses Item 5.02, which covers change
• PTC Therapeutics Enters Material Definitive Agreement — 8-K · Dec 29, 2025 Risk: medium
  On December 29, 2025, PTC Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such
• PTC Therapeutics Swings to Profit on Soaring Collaboration Revenue — 10-Q · Nov 4, 2025 Risk: medium
  PTC Therapeutics, Inc. reported a significant turnaround for the nine months ended September 30, 2025, achieving a net income of $817.609 million, a substantial
• PTC Therapeutics Files 8-K — 8-K · Aug 19, 2025 Risk: low
  On August 19, 2025, PTC Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits, indic
• PTC Therapeutics' Losses Widen Amidst R&D Spend — 10-Q · Aug 7, 2025 Risk: high
  PTC Therapeutics, Inc. reported a net loss of $175.3 million for the three months ended June 30, 2025, a significant increase from the $150.1 million net loss i
• PTC Therapeutics Files 8-K — 8-K · Jul 28, 2025 Risk: low
  On July 28, 2025, PTC Therapeutics, Inc. filed an 8-K report. The filing primarily concerns a Regulation FD Disclosure and the inclusion of Financial Statements
• PTC Therapeutics Files 8-K on Security Holder Vote — 8-K · Jun 17, 2025 Risk: low
  On June 17, 2025, PTC Therapeutics, Inc. filed an 8-K report to announce the submission of matters to a vote of its security holders. The filing does not disclo
• PTC Therapeutics Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
  PTC Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quart
• PTC Therapeutics Files 8-K — 8-K · May 5, 2025 Risk: low
  On May 5, 2025, PTC Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No spe
• PTC Therapeutics Executive Compensation Revealed — DEF 14A · Apr 30, 2025 Risk: medium
  PTC Therapeutics, Inc. filed its DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes i
• PTC Therapeutics Files 8-K Report — 8-K · Mar 28, 2025 Risk: low
  On March 28, 2025, PTC Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statements
• PTC Therapeutics Files 2024 10-K — 10-K · Feb 27, 2025 Risk: medium
  PTC Therapeutics, Inc. filed its 2024 10-K on February 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, located in Warren, NJ, oper
• PTC Therapeutics Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
  On January 13, 2025, PTC Therapeutics, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial state
• PTC Therapeutics Enters Material Definitive Agreement — 8-K · Jan 3, 2025 Risk: medium
  On December 31, 2024, PTC Therapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, headquartered in
• PTC Therapeutics Enters Material Definitive Agreement — 8-K · Dec 2, 2024 Risk: medium
  On November 27, 2024, PTC Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such
• PTC Therapeutics Enters Material Definitive Agreement — 8-K · Nov 27, 2024 Risk: medium
  On November 26, 2024, PTC Therapeutics, Inc. entered into a material definitive agreement. The filing indicates this is a Regulation FD Disclosure and includes
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• PTC Therapeutics Q3 2024: Revenue Up Slightly, Assets Top $1.6B — 10-Q · Nov 7, 2024 Risk: medium
  PTC Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $1.6 billion as of September 30, 2024. For
• PTC Therapeutics Files 8-K Report — 8-K · Oct 18, 2024 Risk: low
  On October 18, 2024, PTC Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD dis
• SC 13G/A Filing — SC 13G/A · Oct 18, 2024
• PTC Therapeutics Amends ClearPoint Neuro Stake — SC 13D/A · Aug 27, 2024 Risk: medium
  PTC Therapeutics, Inc. has filed an amendment (No. 4) to its Schedule 13D concerning ClearPoint Neuro, Inc. The filing, dated August 27, 2024, indicates a chang
• PTC Therapeutics Q2 2024 10-Q Filed — 10-Q · Aug 8, 2024 Risk: medium
  PTC Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $1.6 billion as of June 30, 2024. This filing pr
• PTC Therapeutics Files 8-K Report — 8-K · Jun 28, 2024 Risk: low
  On June 28, 2024, PTC Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclo
• PTC Therapeutics Files 8-K: Material Agreement & Shareholder Vote — 8-K · Jun 20, 2024 Risk: medium
  On June 17, 2024, PTC Therapeutics, Inc. entered into a material definitive agreement. The company also submitted matters to a vote of its security holders and
• PTC Therapeutics Files 8-K Report — 8-K · May 20, 2024 Risk: low
  On May 20, 2024, PTC Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and a Regulation FD Disclosure. No
• PTC Therapeutics, Inc. Files Definitive Proxy Statement — DEF 14A · Apr 26, 2024 Risk: low
  PTC THERAPEUTICS, INC. (PTCT) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Filing is a DEF 14A, a Definitive Proxy Statement. Company Name:
• PTC Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · Apr 25, 2024 Risk: medium
  PTC THERAPEUTICS, INC. (PTCT) filed a Quarterly Report (10-Q) with the SEC on April 25, 2024. PTC Therapeutics, Inc. reported financial results for the quarter
• PTC Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk: medium
  PTC THERAPEUTICS, INC. (PTCT) filed a Annual Report (10-K) with the SEC on February 29, 2024. PTC Therapeutics, Inc. filed its 2023 Annual Report on Form 10-K o
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Wellington Mgmt. Group Adjusts PTC Therapeutics Stake to 9.7% — SC 13G/A · Feb 8, 2024 Risk: low
  Wellington Management Group LLP, a major investment firm, filed an amended SC 13G/A on February 8, 2024, indicating a change in its ownership stake in PTC Thera
• PTC Therapeutics Files 8-K for Regulation FD Disclosure — 8-K · Jan 25, 2024
  PTC Therapeutics, Inc. filed an 8-K on January 25, 2024, primarily under Regulation FD Disclosure and Financial Statements and Exhibits. This filing indicates t
• State Street Amends PTC Therapeutics Stake, Remains Passive Investor — SC 13G/A · Jan 24, 2024
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 24, 2024, indicating its ownership of PTC Therapeutics Inc. common
• FMR LLC Cuts PTC Therapeutics Stake to 2.404% — SC 13G/A · Jan 10, 2024
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have significantly reduced their stake in PTC Therapeutics Inc. As of January 10,
• BlackRock Amends PTC Therapeutics Stake (10th Update) — SC 13G/A · Jan 8, 2024
  BlackRock Inc. has updated its ownership stake in PTC Therapeutics, Inc. through an SC 13G/A filing on January 8, 2024, reflecting its holdings as of December 3
• PTC Therapeutics Files 8-K on Financial Condition & Reg FD Disclosure — 8-K · Jan 8, 2024
  PTC Therapeutics, Inc. filed an 8-K on January 8, 2024, to report on its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'. This fi

Related Companies

SRPT · IONS · NVS · PTC

Frequently Asked Questions